BHM Stock Overview
Provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for BHM from our risk checks.
Bachem Holding AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 6.85 |
| 52 Week High | CHF 9.90 |
| 52 Week Low | CHF 5.04 |
| Beta | 0.72 |
| 11 Month Change | 0% |
| 3 Month Change | -14.37% |
| 1 Year Change | -8.54% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -14.74% |
Recent News & Updates
Recent updates
Shareholder Returns
| BHM | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -9.9% | -7.0% | -1.5% |
| 1Y | -8.5% | 1.3% | 7.9% |
Return vs Industry: BHM underperformed the German Life Sciences industry which returned 2.8% over the past year.
Return vs Market: BHM underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| BHM volatility | |
|---|---|
| BHM Average Weekly Movement | 5.6% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BHM has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BHM's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 2,009 | Thomas Meier | www.bachem.com |
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
Bachem Holding AG Fundamentals Summary
| BHM fundamental statistics | |
|---|---|
| Market cap | €5.49b |
| Earnings (TTM) | €121.45m |
| Revenue (TTM) | €617.85m |
45.2x
P/E Ratio8.9x
P/S RatioIs BHM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BHM income statement (TTM) | |
|---|---|
| Revenue | CHF 577.77m |
| Cost of Revenue | CHF 398.41m |
| Gross Profit | CHF 179.36m |
| Other Expenses | CHF 65.79m |
| Earnings | CHF 113.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 1.51 |
| Gross Margin | 31.04% |
| Net Profit Margin | 19.66% |
| Debt/Equity Ratio | 0% |
How did BHM perform over the long term?
See historical performance and comparison